Abstract
It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor incontrolling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1(AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growthfactor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathwaysmediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS isimplicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit thegrowth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs asnovel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
Keywords: Angiotensin II, renin-angiotensin system, angiotensin II receptor blocker, prostate cancer, hormone-refractorycancer
Mini-Reviews in Medicinal Chemistry
Title: Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Volume: 6 Issue: 7
Author(s): Hiroji Uemura, Hitoshi Ishiguro and Yoshinobu Kubota
Affiliation:
Keywords: Angiotensin II, renin-angiotensin system, angiotensin II receptor blocker, prostate cancer, hormone-refractorycancer
Abstract: It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor incontrolling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1(AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growthfactor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathwaysmediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS isimplicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit thegrowth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs asnovel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
Export Options
About this article
Cite this article as:
Uemura Hiroji, Ishiguro Hitoshi and Kubota Yoshinobu, Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698633
DOI https://dx.doi.org/10.2174/138955706777698633 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comparative Anatomy, Physiology and In Vitro Models of the Blood-Brain and Blood-Retina Barrier
Current Medicinal Chemistry - Central Nervous System Agents Phenotypic Alteration of Bone Marrow HSC and Microenvironmental Association in Experimentally Induced Leukemia
Current Stem Cell Research & Therapy Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Reproductive and Endocrine Effects of p-Nonylphenol and Methoxychlor: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Recent Progress and Challenges in Nanotechnology for Biomedical Applications: An Insight into the Analysis of Neurotransmitters
Recent Patents on Nanotechnology Cubosomes as Carriers for MRI Contrast Agents
Current Medicinal Chemistry Lifelong and Prenatal Effects of Phytoestrogens
Current Bioactive Compounds A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design A Conceptual Model of Psychoneurological Symptom Cluster Variation in Women with Breast Cancer: Bringing Nursing Research to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Nanoradiopharmaceuticals for Bone Cancer Metastasis Imaging
Current Cancer Drug Targets Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry